Anti-Hib-RSV-meningococcus-pneumococcus combination vaccine

Abstract

The invention discloses an anti-Hib-RSV-meningococcus-pneumococcus combination vaccine comprising a Hib-pneumococcus immune intermediate, a meningococcus immune intermediate and a RSV immune intermediate, wherein the Hib-pneumococcus immune intermediate takes pneumococcus expressed protein with high conservatism and immunogenicity as carrier protein and is conjugated to Hib capsular polysaccharides; the meningococcus immune intermediate comprises recombined delta fHbp comprising VA and VB domains of fHbp variant V1 and VC, VD and VE domains of fHbp variant V3; the antigen of the RSV immune intermediate is an RSV membrane surface fusion protein F and / or attachment protein G which can cause body immune response, the nucleic acid sequence expressing the protein antigen is recombined on a nucleic acid vector, the nucleic acid sequence of the recombinant protein takes attenuated intracellular bacteria as a bacteria vector; the immune intermediates of the components are separately prepared into lyophilized powder and then fused and mixed for use.

Description

technical field [0001] The invention relates to an anti-Hib-RSV-meningococcus-pneumococcus combined vaccine, which belongs to the field of biopharmaceuticals. Background technique [0002] 1. Streptococcus pneumoniae and its epidemiology [0003] Streptococcus pneumoniae (Streptococcus pneumoniae) is called for short pneumococcus (Pneumococcus), resides in the nasopharyngeal cavity of normal people, and is the main pathogenic bacteria of bacterial lobar pneumonia, meningitis, otitis media, pneumonia and bronchitis. Diseases caused by pneumococcus have always been a serious global public health problem, with high morbidity and mortality worldwide, especially for children under 2 years old and the elderly. The currently marketed pneumococcal capsular saccharide vaccine and capsular glycoprotein conjugate vaccine are designed based on pneumococcal capsular saccharide, covering the most common serotypes that cause pneumococcal disease. However, the pneumococcal capsular saccha...

AI Technical Summary

Problems solved by technology

[0017] At present, there is a lack of combined immune drugs for various bacteria in the upper respiratory tract infection of the mouth and nose on the market, and upper respiratory tract infection is prone to cause a series of concurrent diseases, and various diseases are closely related and easy to affect each other, especially for susceptible For the general population, the joint disease has a serious impact on physical health, even life-threatening

Images